{"id":"W4386634361","doi":"10.3233/blc-230056","title":"Advancing Clinical Trial Design for Non-Muscle Invasive Bladder Cancer","year":2023,"lang":"en","type":"article","venue":"Bladder Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"EMD Serono; National Cancer Institute; Natera; Medac; Astellas Pharma; Eisai; Genentech; UroGen Pharma; National Institutes of Health; Incyte; Bristol-Myers Squibb; AstraZeneca; University of Texas MD Anderson Cancer Center; Pfizer; Patient-Centered Outcomes Research Institute","keywords":"Bladder cancer; Medicine; Food and drug administration; Clinical trial; Drug; Intensive care medicine; Oncology; Clinical research; Cancer; Internal medicine; Pharmacology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.000628396,0.0004457996,0.0008772585,0.0002000967,0.0002452417,0.00004939956,0.0002233861,0.0003079745,0.001560403],"category_scores_gemma":[0.0003723881,0.0003791118,0.000525059,0.0006291119,0.0001448914,0.0001918187,0.00006802739,0.000340813,0.0002448522],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000336221,"about_ca_system_score_gemma":0.00238903,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006553889,"about_ca_topic_score_gemma":0.0006308647,"domain_scores_codex":[0.9966505,0.0001100487,0.0008107281,0.0009296883,0.0005100403,0.0009890581],"domain_scores_gemma":[0.9976908,0.0007224074,0.0002345269,0.0005823119,0.0003111851,0.0004587591],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.06074853,0.001096959,0.01105219,0.0004472726,0.003728508,0.0001951646,0.001627486,0.0008183431,0.004902749,0.00004569736,0.758916,0.1564211],"study_design_scores_gemma":[0.4545351,0.01524901,0.0902105,0.001900664,0.006345088,0.00003306671,0.0020331,0.004645126,0.03143816,0.001720132,0.3890481,0.002841967],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9020908,0.007671253,0.01232401,0.02005276,0.02169436,0.02507317,0.001444155,0.001747469,0.007901952],"genre_scores_gemma":[0.9035039,0.0122192,0.006320772,0.01414878,0.01722647,0.01941298,0.0002666285,0.0005968926,0.02630438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3937866,"threshold_uncertainty_score":0.9998661,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1165162165901714,"score_gpt":0.4196531955455624,"score_spread":0.3031369789553909,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}